To statin or to non-statin in coronary disease-considering absolute risk is the answer

Atherosclerosis

Volumn 195, Issue 1, 2007, Pages 1-6

  Rembold, Christopher M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Absolute risk reduction; Fibric acid; Mediterranean diet; Niacin; Relative risk reduction

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; STATIN;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE COURSE; HUMAN; ISCHEMIC HEART DISEASE; MEDITERRANEAN DIET; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; THROMBOSIS;

ACUTE CORONARY SYNDROME; ASPIRIN; ATHEROSCLEROSIS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIET; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; RISK;

EID: 35248829989     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.09.009     Document Type: Review

References (30)

1. LaRosa J.C., Grundy S.M., Waters D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
2. Pedersen E.B., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs. usual dose simvastatin for secondary prevention after myocardial infarction. JAMA 294 (2005) 2437-2445
3. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
4. Sacks H.S., Berrier J., Reitman D., Ancona-Berk V.A., and Chalmers T.C. Meta-analyses of randomized controlled trials. N Engl J Med 316 (1987) 450-455
5. McQuay H.J., and Moore R.A. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 126 (1997) 712-720
6. MRC working party. Medical research council trial in the treatment of hypertension in older adults: principal results. Br Med J 304 (1992) 405-412
7. Rembold C.M. A number needed to treat (NNT) analysis of the prevention of myocardial infarction and death by dyslipidemic therapy. J Fam Prac 42 (1996) 577-586
8. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
9. The Long-term Intervention with Pravastatin in Ischaemic Diseaese (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
10. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
11. Collins R., Armitage J., Parish S., Sleight P., and Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
12. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
13. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
14. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels-results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
15. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
16. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
17. Delorgeril M., Renaud S., Mamelle N., et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 343 (1994) 1454-1459
18. de Lorgeril M., Salen P., Martin J.L., Monjaud I., Delaye J., and Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction-final report of the Lyon Diet Heart Study. Circulation 99 (1999) 779-785
19. Buchwald H., and POSCH group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 323 (1990) 946-955
20. Valagussa F., Franzosi M.G., Geraci E., et al. Dietary supplementation with n-3 polyunsaturated fatty acids and Vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455
21. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
22. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
23. Cannon C.P., Braunwald E., Mccabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
24. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes-phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
25. Barter P., Kastelein J., Nunn A., and Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168 (2003) 195-211
26. Anonymous The Framingham Study. The epidemiology of atherosclerotic disease (1980), Harvard University Press, Cambridge, MA
27. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high-levels of apolipoprotein-B. N Engl J Med 323 (1990) 1289-1298
28. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
29. Zhao X.Q., Yuan C., Hatsukami T.S., et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI-a case-control study. Arterioscler Thromb Vasc Biol 21 (2001) 1623-1629
30. Whitney E.J., Krasuski R.A., Personius B.E., et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005) 95-104